A new virus treatment for pancreatic cancer
A novel oncolytic virus for pancreatic cancer immunotherapy
This study is exploring a new way to treat pancreatic cancer using specially designed viruses that can kill cancer cells and help the immune system fight the tumor better, aiming to improve outcomes for patients who currently have limited treatment options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lsu Health Sciences Center NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project ID | NIH-11192537 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating pancreatic cancer using engineered oncolytic viruses. These viruses are designed to not only kill cancer cells directly but also to enhance the immune response against the tumor. By converting 'cold' tumors, which do not respond well to traditional immunotherapy, into 'hot' tumors that can be effectively targeted by the immune system, this project aims to improve treatment outcomes for patients. The study will involve bioengineering a specific virus to express enzymes that can help overcome the challenges posed by the tumor microenvironment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic cancer who have not responded well to standard treatments.
Not a fit: Patients with early-stage pancreatic cancer who are candidates for surgical resection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new and effective treatment option for patients with pancreatic cancer, potentially improving survival rates and quality of life.
How similar studies have performed: Other research has shown promising results using oncolytic viruses in treating various cancers, indicating potential for success in this novel approach.
Where this research is happening
New Orleans, United States
- Lsu Health Sciences Center — New Orleans, United States (Active)
Researchers
- Principal investigator: Moaven, Omeed — Lsu Health Sciences Center
- Study coordinator: Moaven, Omeed
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.